Limited coverage drugs – risankizumab
Special Authority requests can now be submitted online. It's simple and quick!
Learn more or log in
|
Generic name |
risankizumab |
|---|---|
|
Strength |
pre-filled syringe: 75 mg/0.83 mL pre-filled syringe, pre-filled pen: 150 mg/1 mL |
|
Form |
syringe (subcutaneous injection) pen (subcutaneous injection) |
| Special Authority criteria | Approval period |
|---|---|
|
For the treatment of moderate to severe plaque psoriasis, according to established criteria described in Special Authority request form 5380, when prescribed by a dermatologist |
First approval: 16 weeks Renewal: 1 year |
Practitioner exemptions
- None
Special notes
- None
